Control of growth hormone and IGF1 in patients with acromegaly in the UK: Responses to medical treatment with somatostatin analogues and dopamine agonists

Clinical Endocrinology

Volumn 79, Issue 5, 2013, Pages 689-699

  Howlett, Trevor A ^a   Willis, Debbie ^a   Walker, Gillian ^a   Wass, John A H ^a   Trainer, Peter J ^a  

^a Society for Endocrinology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CHILD; CLINICAL PRACTICE; DOSE RESPONSE; ENDOCRINE SURGERY; FEMALE; GROWTH HORMONE RELEASE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; UNITED KINGDOM;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DOPAMINE AGONISTS; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; SOMATOSTATIN; YOUNG ADULT;

EID: 84885216797     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12207     Document Type: Article

References (21)

1. Sherlock, M., Ayuk, J., Tomlinson, J.W., et al,. (2010) Mortality in patients with pituitary disease. Endocrine Reviews, 31, 301-342.
2. Bates, A.S., Van't Hoff, W., Jones, J.M., et al,. (1993) An audit of outcome of treatment in acromegaly. The Quarterly journal of medicine, 86, 293-299.
3. Orme, S.M., McNally, R.J., Cartwright, R.A., et al,. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730-2734.
4. Ayuk, J., Clayton, R.N., Holder, G., et al,. (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 1613-1617.
5. Holdaway, I.M., Bolland, M.J., &, Gamble, G.D., (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 159, 89-95.
6. Giustina, A., Barkan, A., Casanueva, F.F., et al,. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526-529.
7. Melmed, S., Casanueva, F.F., Cavagnini, F., et al,. (2002) Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism, 87, 4054-4058.
8. Melmed, S., Colao, A., Barkan, A., et al,. (2009) Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism, 94, 1509-1517.
9. Giustina, A., Chanson, P., Bronstein, M.D., et al,. (2010) A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism, 95, 3141-3148.
10. Giustina, A., Bronstein, M.D., Casanueva, F.F., et al,. (2011) Current management practices for acromegaly: an international survey. Pituitary, 14, 125-133.
11. Bates, P.R., Carson, M.N., Trainer, P.J., et al,.; UK National Acromegaly Register Study Group (UKAR-2). (2008) Wide variation in surgical outcomes for acromegaly in the UK. Clinical Endocrinology, 68, 136-142.
12. Jenkins, P.J., Bates, P., Carson, M.N., et al,. (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 91, 1239-1245.
13. Wass, J.A.H., Thorner, M.O., Morris, D.V., et al,. (1977) Long-term treatment of acromegaly with bromocriptine. British Medical Journal, 1, 875-878.
14. Jackson, S.N., Fowler, J., &, Howlett, T.A., (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clinical Endocrinology, 46, 745-749.
15. Abs, R., Verhelst, J., Maiter, D., et al,. (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism, 83, 374-378.
16. Sandret, L., Maison, P., &, Chanson, P., (2011) Place of cabergoline in acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 96, 1327-1335.
17. Murray, R.D., &, Melmed, S., (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Journal of Clinical Endocrinology and Metabolism, 93, 2957-2968.
18. Schofl, C., Franz, H., Grussendorf, M., et al,. (2012) Long-Term-Outcome in Patients with Acromegaly: analysis of 1344 Patients from the German Acromegaly Register. European Journal of Endocrinology, 168, 39-47.
19. Sesmilo, G., Gaztambide, S., Venegas, E., et al,. (2013) Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary, 16, 115-121.
20. Bex, M., Abs, R., T'Sjoen, G., et al,. (2007) AcroBel-the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. European Journal of Endocrinology, 157, 399-409.
21. Ben-Shlomo, A., Sheppard, M.C., Stephens, J.M., et al,. (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary, 14, 284-294.